Different origins of chronic heart failure in patients with chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2016-26-1-38-45
Abstract
The aim of this study was to analyze prevalence, clinical course and pathogenesis of chronic heart failure (CHF) in patients with chronic obstructive pulmonary disease (COPD). Methods. The study involved 309 patients with COPD who underwent spirometry and Doppler echocardiography. Natriuretic peptide level was measured in blood. Results.One hundred and twelve (36.2%) patients had CHF. Patients with comorbidity were older, had higher body mass index, longer and more severe smoking history. Dyspnea as one of the main COPD symptoms existed for longer period in patients with COPD and CHF. CHF was related to severity of the airflow limitation. There was no difference between patients with different origin of CHF. The rate of hypertension was similar in COPD patients with and without CHF, but the duration of hypertension was almost twice as higher in patients with CHF. The left ventricular ejection fraction (LV EF) was significantly lower in COPD patients with CHF compared to those without CHF and was significantly lower in patients with ischaemic CHF compared to CHF of another origin. Also, COPD patients with CHF had significantly lower physical tolerance measured by 6-min walk test and more severe hypoxemia. Conclusion. Prevalence of CHF in COPD patients is quite high. CHF is caused both by concomitant cardiovascular disease (coronary heart disease, hypertension, etc.) and actually by progressive chronic cor pulmonale. Unaffected LV EF is seen more often in COPD patients; however, decreased LV EF is associated with coronary heart disease. Development of CHF in COPD patients is also associated with such risk factors as smoking, severe bronchial obstruction, hypoxemia, and tachycardia.
About the Authors
N. A. Karoli
V.I.Razumovskiy Saratov State Medical University, Healthcare Ministry of Russia: 112, Bol. Kazach'ya str., Saratov, 410012, Russia
Russian Federation
Russian Federation
MD, Professsor at Department of Hospital Internal Medicine, Medical Faculty, V.I.Razumovskiy Saratov State Medical University, Healthcare Ministry of Russia; tel.: (917) 213-69-86;
A. V. Borodkin
V.I.Razumovskiy Saratov State Medical University, Healthcare Ministry of Russia: 112, Bol. Kazach'ya str., Saratov, 410012, Russia
Russian Federation
Russian Federation
PhD student at Department of Hospital Internal Medicine, Medical Faculty, V.I.Razumovskiy Saratov State Medical University, Healthcare Ministry of Russia; tel.: тел.: (917) 981-32-70;
A. P. Rebrov
V.I.Razumovskiy Saratov State Medical University, Healthcare Ministry of Russia: 112, Bol. Kazach'ya str., Saratov, 410012, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Department of Hospital Internal Medicine, Medical Faculty, V.I.Razumovskiy Saratov State Medical University, Healthcare Ministry of Russia; tel.: (845) 249-14-37;
References
1. Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 269–280.
2. Jessup M., Brozena S. Medical progress: heart failure. N. Engl. J. Med. 2003; 348: 2007–2018.
3. Higgins M., Keller J.B., Wagenknecht L.E. et al. Pulmonary function and cardiovascular risk factor relationship in black and in white young men and women. The CARDIA Study. Chest. 1991; 99: 315–322.
4. Jousilahti P., Vartiainen E., Tuomilehto J., Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 1996; 348: 567–572.
5. Cook D.G., Shaper A.G. Breathlessness, lung function and the risk of heart attack. Eur. Heart. J. 1988; 9: 1215–1222.
6. Hole D.J., Watt G.C.M., Davey Smith G. et al. Impaired lung function and mortality risk in men and women: find ings from the Renfrew and Paisley prospective population study. Br. Med. J. 1996; 313: 711–715.
7. Shunemann H.J., Dorn J., Grant B.J. et al. Pulmonary function is a long term predictor of mortality in the general population. Chest. 2000; 118: 656–664.
8. Knuiman M.W., James A.L., Divitinin M.L. et al. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann. Epidemiol. 1999; 9: 297–306.
9. Sil'vestrov V.P., Surovov Yu.A., Semin S.N. Chronic cor pulmonale: mechanisms of development and progress. Terapevticheskiy arkhiv. 1991; 3: 103–108 (in Russian).
10. Weitzenblum E., Hirth C., Ducolone A. et al. Prognosis value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981; 36: 752–758.
11. National guidelines of Society of Specialists for Heart Failure, Russian Society of Cardiologists and Russian Scientific Medical Society of Therapeutists on therapy of chronic heart failure (the 4th ed.). Serdechnaya Nedosta tochnost'. 2013; 81: 1–94 (in Russian).
12. Rutten F.H., Cramer M.J., Lammers J.W. et al. Heart fail ure and chronic obstructive pulmonary disease: An ignored combination? Eur. J. Heart Fail. 2006; 8 (7): 706–711.
13. McCullough P.A., Hollander J.E., Nowak R.M. et al. Uncovering heart failure in patients with a history of pul monary disease: rationale for the early use of B type natri uretic peptide in the emergency department. Acad. Emerg. Med. 2003; 10 (3): 198–204.
14. Rutten F.H., Cramer M.J., Grobbee D.E. et al. Unrecognised heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur. Heart J. 2005; 26: 1887–1894.
15. Hawkins N.M., Petrie M.C., Jhund P.S. et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pit falls and epidemiology. Eur. J. Heart Fail. 2009; 11 (2): 130–139.
16. Macchia A., Rodriguez Moncalvo J.J., Kleinert M. et al. Unrecognised ventricular dysfunction in COPD. Eur. Respir. J. 2012; 39 (1): 51–58.
17. Barbera J.A., Peinado V., Santos S. Pulmonary hyperten sion in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 892–905.
18. Morrell N.W., Danilov S.M., Satyan K.B. et al. Right ven tricular angiotensin converting enzyme activity and expres sion is increased during hypoxic pulmonary hypertension. Cardiovasc. Res. 1997; 34: 393.
19. Swedberg K. Pure heart rate reduction: further perspectives in heart failure. Eur. Heart J. 2007; 9 (Suppl. F): 20–24.
20. Swedberg K., Komajda M., Ichael Böhm M. et al. Iva bradine and outcomes in chronic heart failure (SHIFT): a randomised placebo controlled study. Lancet. 2010; 376, Issue 9744: 875–885.
Review
For citations:
Karoli N.A., Borodkin A.V., Rebrov A.P. Different origins of chronic heart failure in patients with chronic obstructive pulmonary disease. PULMONOLOGIYA. 2016;26(1):38-45. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-1-38-45
Views:
1891
Email this article 